Melissa Damschroder

Melissa Damschroder

Auto-generated profile, based on publicly available information

Melissa Damschroder

Department of Antibody Discovery and Protein Engineering, MedImmune LLC, Gaithersburg, Maryland, United States of America

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2010 in Journal of Allergy and Clinical Immunology
Verified
Journal Article
Closed access
RKRoland Kolbeck
Roland Kolbeck
AKAlexander Kozhich
Alexander Kozhich
MKMasamichi Koike
Masamichi Koike
LPLi Peng
Li Peng
CACecilia K. Andersson
Cecilia K. Andersson
ACAnthony J. Coyle
Anthony J. Coyle

1 March 2014 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
VOVaheh Oganesyan
Vaheh Oganesyan
MDMelissa M. Damschroder
Melissa M. Damschroder
KCKimberly E. Cook
Kimberly E. Cook
QLQing Li
Qing Li
CGChangshou Gao
Changshou Gao
WDWilliam F. Dall'ACqua
William F. Dall'ACqua
We report the three-dimensional structure of human neonatal Fc receptor (FcRn) bound concurrently to its two known ligands. More particularly, we solved the crystal structure of the complex between human FcRn, wild-type human serum albumin (HSA), and a human Fc engineered for improved pharmacokinetics properties (Fc-YTE). The crystal structure of human FcRn bound to wild-type HSA alone is also presented. HSA domain III exhibits an extensive interface of contact with FcRn, whereas domain I plays a lesser role. A molecular explanation for the HSA recycling mechanism is provided with the identification of FcRn His161 as the only potential direct contributor to the corresponding pH-dependent process. At last, this study also allows an accurate structural definition of residues considered for decades as important to the human IgG/FcRn interaction and reveals Fc His310 as a significant contributor to pH-dependent binding. Finally, we explain various structural mechanisms by which several Fc mutations (including YTE) result in increased human IgG binding to FcRn. Our study provides an unprecedented relevant understanding of the molecular basis of human Fc interaction with human FcRn.

11 July 2014 in Immunology
Verified
Journal Article
Closed access
PDF file
WAW. Mark Abbott
W. Mark Abbott
MDMelissa M. Damschroder
Melissa M. Damschroder
DLDavid C. Lowe
David C. Lowe

1 February 2014 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
LHL. Hua
L. Hua
JHJ. J. Hilliard
J. J. Hilliard
YSY. Shi
Y. Shi
CTC. Tkaczyk
C. Tkaczyk
LCL. I. Cheng
L. I. Cheng
BSB. R. Sellman
B. R. Sellman
Alpha-toxin (AT) is a major virulence factor in the disease pathogenesis ofStaphylococcus aureus. We previously identified a monoclonal antibody (MAb) against AT that reduced disease severity in a mouse dermonecrosis model. Here, we evaluate the activity of an affinity-optimized variant, LC10, in a mouse model ofS. aureuspneumonia. Passive immunization with LC10 increased survival and reduced bacterial numbers in the lungs and kidneys of infected mice and showed protection against diverseS. aureusclinical isolates. The lungs ofS. aureus-infected mice exhibited bacterial pneumonia, including widespread inflammation, whereas the lungs of mice that received LC10 exhibited minimal inflammation and retained healthy architecture. Consistent with reduced immune cell infiltration, LC10-treated animals had significantly lower (P< 0.05) proinflammatory cytokine and chemokine levels in the bronchoalveolar lavage fluid than did those of the control animals. This reduction in inflammation and damage to the LC10-treated animals resulted in reduced vascular protein leakage and CO2levels in the blood. LC10 was also assessed for its therapeutic activity in combination with vancomycin or linezolid. Treatment with a combination of LC10 and vancomycin or linezolid resulted in a significant increase (P< 0.05) in survival relative to the monotherapies and was deemed additive to synergistic by isobologram analysis. Consistent with improved survival, the lungs of animals treated with antibiotic plus LC10 exhibited less inflammatory tissue damage than those that received monotherapy. These data provide insight into the mechanisms of protection provided by AT inhibition and support AT as a promising target for immunoprophylaxis or adjunctive therapy againstS. aureuspneumonia.

15 July 2006 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
WDWilliam F. Dall’acqua
William F. Dall’acqua
KCKimberly E Cook
Kimberly E Cook
MDMelissa M. Damschroder
Melissa M. Damschroder
RWRobert M. Woods
Robert M. Woods
HWHerren Wu
Herren Wu
We report here the engineering of a humanized anti-human EphA2 mAb (mAb 12G3H11) in an effort to explore the relationship between the hinge of a human IgG1 and its effector functions. mAb 12G3H11, used here as a model, is directed against the human receptor tyrosine kinase EphA2, which is an actively investigated target for cancer therapy due to its up-regulation in many cancer cells. Various rational modifications were introduced into the hinge region of mAb 12G3H11. These mutations were predicted to modulate the hinge’s length, flexibility, and/or biochemical properties. We show that the upper and middle hinge both play important, although functionally distinct roles. In particular, middle hinge modifications predicted to decrease its rigidity or length as well as eliminating either one of its two cysteine residues had a strong negative impact on C1q binding and complement-dependent cytotoxicity. Disruption of covalent bonds between both H chains may account in part for these effects. We also describe middle hinge mutants with a significantly decreased ability to bind FcγRIIIA and trigger Ab-dependent cell-mediated cytotoxicity. Conversely, we also generated upper hinge mutants exhibiting an increase in C1q binding and complement-dependent cytotoxicity activity. Therefore, this approach represents a novel strategy to fine-tune the biological activity of a given human IgG1. We also define, for the first time in such a systematic fashion, the relationship between various characteristics of the middle and upper hinge and the corresponding effector functions.

1 October 2010 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
RHRonald Herbst
Ronald Herbst
YWYue Wang
Yue Wang
SGSandra Gallagher
Sandra Gallagher
NMNanette Mittereder
Nanette Mittereder
EKEllen Kuta
Ellen Kuta
ACAnthony J. Coyle
Anthony J. Coyle
The pan B-cell surface antigen CD19 is an attractive target for therapeutic monoclonal antibody (mAb) approaches. We have generated a new afucosylated anti-human (hu)CD19 mAb, MEDI-551, with increased affinity to human FcγRIIIA and mouse FcγRIV and enhanced antibody-dependent cellular cytotoxicity (ADCC). During in vitro ADCC assays with B-cell lines, MEDI-551 is effective at much lower mAb concentrations than the fucosylated parental mAb anti-CD19-2. Furthermore, the afucosylated CD19 mAb MEDI-551 depleted B cells from normal donor peripheral blood mononuclear cell samples in an autologous ADCC assay, as well as blood and tissue B cells in human CD19/CD20 double transgenic (Tg) mice at lower concentrations than that of the positive control mAb rituximab. In huCD19/CD20 Tg mice, both macrophage-mediated phagocytosis and complement-dependent cytotoxicity contribute to depletion with rituximab; MEDI-551 did not require complement for maximal B-cell depletion. Furthermore, extended B-cell depletion from the blood and spleen was achieved with MEDI-551, which is probably explained by bone marrow B-cell depletion in huCD19/CD20 Tg mice relative to the control mAb rituximab. In summary, MEDI-551 has potent B-cell-depleting activity in vitro and in vivo and may be a promising new approach for the treatment of B-cell malignancies and autoimmune diseases.